Novonesis Acquires dsm-firmenich's Share in Major Deal
Deal News | Feb 14, 2025 | Legal Community Swiss
Novonesis, a Danish biotechnology company resulting from the merger of Chr. Hansen and Novozymes, has acquired dsm-firmenich's share of the Feed Enzyme Alliance. The acquisition was advised by Baker McKenzie and the transaction was valued at EUR 1.5 billion. The deal enables Novonesis to take control of the Alliance's sales and distribution operations, thereby enhancing its position in the animal biosolutions sector. The legal advisory team was spearheaded by Baker McKenzie's global head of M&A, Jannan Crozier, supported by a team spread across several cities including London, Amsterdam, Brussels, and Zurich.
Sectors
- Biotechnology
- Legal Advisory
Geography
- Denmark – Novonesis is headquartered in Bagsværd, Denmark, and represents the primary location involved in the transaction.
- Netherlands – dsm-firmenich, the selling company, is based in the Netherlands, making this country relevant to the geography of the transaction.
- United Kingdom – Part of the Baker McKenzie team advising on the deal was based in London, UK.
Industry
- Biotechnology – This industry is relevant because Novonesis operates in the biotech sector, primarily focusing on solutions across the animal biosolutions value chain.
- Legal Advisory – Baker McKenzie, a legal advisory firm, played a pivotal role in advising Novonesis on the transaction.
Financials
- EUR 1.5 billion – The valuation of the transaction involving the acquisition of dsm-firmenich's share in the Feed Enzyme Alliance by Novonesis.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Novonesis | Buyer | Company | A global biotechnology company that acquired dsm-firmenich's share in the Feed Enzyme Alliance. |
| dsm-firmenich | Seller | Company | A company that sold its share in the Feed Enzyme Alliance to Novonesis. |
| Baker McKenzie | Legal Advisor | Company | An international law firm advising Novonesis on the transaction. |